The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

328

Enrollment

INDUSTRY

Sponsor class

Conditions

ECG Effects

Interventions

DRUG: Buprenorphine transdermal patch
DRUG: Naltrexone tablet
DRUG: Placebos (for TDS and for naltrexone and for moxifloxacin)
DRUG: Moxifloxacin tablet

Sponsor

Purdue Pharma LP